JP2013515013A5 - - Google Patents

Download PDF

Info

Publication number
JP2013515013A5
JP2013515013A5 JP2012545019A JP2012545019A JP2013515013A5 JP 2013515013 A5 JP2013515013 A5 JP 2013515013A5 JP 2012545019 A JP2012545019 A JP 2012545019A JP 2012545019 A JP2012545019 A JP 2012545019A JP 2013515013 A5 JP2013515013 A5 JP 2013515013A5
Authority
JP
Japan
Prior art keywords
antibody
amino acid
acid sequence
antibody fragment
fragment according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012545019A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013515013A (ja
JP5992831B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2010/001741 external-priority patent/WO2011075789A1/en
Publication of JP2013515013A publication Critical patent/JP2013515013A/ja
Publication of JP2013515013A5 publication Critical patent/JP2013515013A5/ja
Application granted granted Critical
Publication of JP5992831B2 publication Critical patent/JP5992831B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012545019A 2009-12-24 2010-12-23 非機能性オリゴマーp2x7受容体に対する抗体 Active JP5992831B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2009906286A AU2009906286A0 (en) 2009-12-24 Anti P2X7 receptor antibodies and fragments thereof
AU2009906286 2009-12-24
PCT/AU2010/001741 WO2011075789A1 (en) 2009-12-24 2010-12-23 Antibodies to non-functional oligomeric p2x7 receptors

Publications (3)

Publication Number Publication Date
JP2013515013A JP2013515013A (ja) 2013-05-02
JP2013515013A5 true JP2013515013A5 (enExample) 2014-02-13
JP5992831B2 JP5992831B2 (ja) 2016-09-14

Family

ID=44194835

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012545019A Active JP5992831B2 (ja) 2009-12-24 2010-12-23 非機能性オリゴマーp2x7受容体に対する抗体

Country Status (9)

Country Link
US (2) US8835609B2 (enExample)
EP (2) EP3321285B1 (enExample)
JP (1) JP5992831B2 (enExample)
CN (1) CN102762595B (enExample)
AU (1) AU2010336032C1 (enExample)
BR (1) BR112012015561B1 (enExample)
CA (1) CA2784345C (enExample)
ES (2) ES2667003T3 (enExample)
WO (1) WO2011075789A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1360203T3 (da) 2001-01-17 2009-04-20 Intreat Pty Ltd Antistoffer mod ikke-funktionel P2X7-receptordiagnose og behandling af cancerlidelser og andre tilstande
JP5670192B2 (ja) 2007-09-14 2015-02-18 バイオセプター・インターナショナル・リミテッド 新規p2x7エピトープ
ATE542139T1 (de) 2007-09-14 2012-02-15 Biosceptre Int Ltd Purinerge (p2x)-rezeptoren in extrazellulärer körperflüssigkeit
KR101701300B1 (ko) 2008-07-04 2017-02-01 바이오셉터 (어스트) 피티와이 엘티디 항­p2x7 펩티드 및 에피토프
ES2904911T3 (es) 2009-08-20 2022-04-06 Biosceptre Aust Pty Ltd Anticuerpos anti-receptor P2X7 y fragmentos de los mismos
BR112012015561B1 (pt) 2009-12-24 2019-11-12 Biosceptre International Ltd anticorpos dirigidos contra receptores p2x7 oligoméricos não funcionais
CN106310245A (zh) 2010-09-10 2017-01-11 生物权威(澳大利亚)有限责任公司 陪伴动物治疗
US9566318B2 (en) 2011-07-01 2017-02-14 Biosceptre (Aust) Pty Ltd Combination therapy
JPWO2014003137A1 (ja) * 2012-06-27 2016-06-02 旭化成メディカル株式会社 高アフィニティー抗体、及びその製造方法
JP6790062B2 (ja) * 2015-04-02 2020-11-25 バイオセプター・(ユーケー)・リミテッド 疼痛治療
KR20180043841A (ko) * 2015-09-11 2018-04-30 카리나 바이오테크 피티와이 엘티디 키메라 항원 수용체 및 이의 용도
WO2018071959A1 (en) 2016-10-21 2018-04-26 Biosceptre (Uk) Limited Cytotoxic particles
WO2019165326A1 (en) * 2018-02-23 2019-08-29 REMD Biotherapeutics, Inc Calcitonin gene-related peptide (cgrp) antagonist antibodies
WO2019229296A1 (en) 2018-05-29 2019-12-05 Teknologian Tutkimuskeskus Vtt Oy Anti-thyroid hormone (t4) recombinant antibody or antigen binding fragment
CN110054691B (zh) * 2019-05-09 2021-09-07 潍坊医学院 一种抗人p2rx7单克隆抗体的杂交瘤细胞系
WO2021019222A1 (en) * 2019-07-26 2021-02-04 Biosceptre (Uk) Limited P2x7 receptor targeted therapy
US20250281611A1 (en) * 2021-03-11 2025-09-11 Biosceptre ( Aust ) Pty Ltd Novel cell therapy system
CN117881421A (zh) * 2021-09-01 2024-04-12 生物权威(澳大利亚)有限责任公司 用于刺激免疫活性的方法和组合物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE920765A1 (en) 1991-03-12 1992-09-23 Scripps Research Inst Cell surface receptors homologous to coagulation factors v¹and viii
EP0760850A1 (en) 1994-05-27 1997-03-12 Glaxo Group Limited P2x RECEPTORS (PURINOCEPTOR FAMILY)
EP0854923A2 (en) 1995-08-09 1998-07-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Isolated nucleic acid molecules useful as leukemia markers and in breast cancer prognosis
WO1997041222A1 (en) 1996-04-30 1997-11-06 Smithkline Beecham P.L.C. HUMAN P2x4 RECEPTOR SPLICE-VARIANTS
US6303338B1 (en) 1996-08-16 2001-10-16 Human Genome Sciences, Inc. Pancreas-derived plasminogen activator inhibitor
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
JP3885177B2 (ja) 1997-03-26 2007-02-21 大塚製薬株式会社 ヒト遺伝子
US6133434A (en) 1997-04-28 2000-10-17 Glaxo Group Limited Purinergic receptor
US6329503B1 (en) 1998-06-01 2001-12-11 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
DE19829473C2 (de) 1998-07-01 2000-08-10 Magnus Von Knebel Doeberitz Ch Verfahren zur frühen Diagnose von Carcinomen
EP1157038A4 (en) 1999-02-26 2005-01-19 Smithkline Beecham Corp CLONING OF A P2Y-LIKE 7TM RECEPTOR (AXOR17)
AUPP991199A0 (en) 1999-04-21 1999-05-13 University Of Sydney, The Methods for diagnosing pre-cancerous and cancerous conditions
AU1339701A (en) 1999-10-22 2001-05-08 Lifespan Biosciences, Inc. Anti-cancer nucleic acid and protein targets
AUPR201500A0 (en) 2000-12-11 2001-01-11 Biosceptre Pty Ltd Methods for identifying pre-neoplastic and neoplastic states in mammals
DK1360203T3 (da) 2001-01-17 2009-04-20 Intreat Pty Ltd Antistoffer mod ikke-funktionel P2X7-receptordiagnose og behandling af cancerlidelser og andre tilstande
AU2002322192B2 (en) * 2001-09-03 2008-05-01 Biosceptre International Limited Antibodies to non-functional P2X7receptor, diagnosis and treatment of cancers and other conditions
DK1473367T3 (da) 2003-04-17 2007-10-01 Affectis Pharmaceuticals Ag Midler og fremgangsmåder til diagnosticering og behandling af effektive lidelser
CA2607541A1 (en) 2005-05-05 2006-12-28 Medicure International Inc. Inhibition of atp-mediated, p2x7 dependent pathways by pyridoxal-5-phosphaste and vitamin b6 related compounds
US7767789B2 (en) 2005-06-02 2010-08-03 University Hopitals of Cleveland Truncated proteins as cancer markers
WO2007027957A2 (en) 2005-08-31 2007-03-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
JP2010505426A (ja) 2006-10-10 2010-02-25 バイオスセプター インターナショナル リミテッド 非機能性p2x7受容体に対する抗体を産生するハイブリドーマ
WO2008043146A1 (en) * 2006-10-10 2008-04-17 Biosceptre International Limited Antibodies against non functional p2x7 receptor
JP5670192B2 (ja) 2007-09-14 2015-02-18 バイオセプター・インターナショナル・リミテッド 新規p2x7エピトープ
ATE542139T1 (de) 2007-09-14 2012-02-15 Biosceptre Int Ltd Purinerge (p2x)-rezeptoren in extrazellulärer körperflüssigkeit
KR101701300B1 (ko) 2008-07-04 2017-02-01 바이오셉터 (어스트) 피티와이 엘티디 항­p2x7 펩티드 및 에피토프
ES2904911T3 (es) 2009-08-20 2022-04-06 Biosceptre Aust Pty Ltd Anticuerpos anti-receptor P2X7 y fragmentos de los mismos
BR112012015561B1 (pt) 2009-12-24 2019-11-12 Biosceptre International Ltd anticorpos dirigidos contra receptores p2x7 oligoméricos não funcionais
US8828944B2 (en) 2010-04-22 2014-09-09 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
CN106310245A (zh) 2010-09-10 2017-01-11 生物权威(澳大利亚)有限责任公司 陪伴动物治疗
US9566318B2 (en) 2011-07-01 2017-02-14 Biosceptre (Aust) Pty Ltd Combination therapy

Similar Documents

Publication Publication Date Title
JP2013515013A5 (enExample)
JP2014511179A5 (enExample)
JP2013502204A5 (enExample)
JP2014512809A5 (enExample)
ME02678B (me) Antitijela na ox-40 i postupci njihove primjene
JP2017507652A5 (enExample)
JP2009532336A5 (enExample)
JP2017052784A5 (enExample)
JP2013506428A5 (enExample)
RU2017126476A (ru) Новые модуляторы и способы их применения
JP2020522261A5 (enExample)
JP2014526898A5 (enExample)
JP2009225799A5 (enExample)
JP2016516400A5 (enExample)
JP2013198490A5 (enExample)
JP2013538057A5 (enExample)
JP2015530971A5 (enExample)
JP2018504105A5 (enExample)
NZ598670A (en) Antibodies against glucagon receptor and their use
NZ608206A (en) Antibodies that bind myostatin, compositions and methods
JP2018512379A5 (enExample)
HRP20211444T1 (hr) Anti-dll3 antitijelo
JP2011207882A5 (enExample)
JP2017500028A5 (enExample)
JP2017519759A5 (enExample)